Data Sheet (Cat.No.T36750)

TargetMol

Didesmethylrocaglamide

Chemical Properties



CAS No. : 177262-30-5

Formula: C27H27NO7

Molecular Weight: 477.51

Storage: Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Didesmethylrocaglamide is a and selective small molecule inhibitor of the eukaryotic translation initiation factor 4A (eIF4A) that effectively blocks the protein translation machinery to exert robust anti-proliferative and pro-apoptotic activities against malignant peripheral nerve sheath tumors and various sarcoma lineages.
Targets(IC50)	Others
In vitro	In cell proliferation assays, Didesmethylrocaglamide inhibited osteosarcoma cell growth and induced apoptosis as a protein translation inhibitor [1].

Solubility Information

Solubility	DMSO: 80 mg/mL (167.54 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2.4 mg/mL (5.03 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0942 mL	10.471 mL	20.942 mL
5 mM	0.4188 mL	2.0942 mL	4.1884 mL
10 mM	0.2094 mL	1.0471 mL	2.0942 mL
50 mM	0.0419 mL	0.2094 mL	0.4188 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Long-Sheng Chang, et al. Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. Mol Cancer Ther. 2020 Mar;19(3):731-741.
Long-Sheng Chang, et al. Abstract 1950: The eIF4A inhibitors didesmethylrocaglamide and rocaglamide as effective treatments for pediatric bone and soft-tissue sarcomas. Cancer Res 2020;80(16 Suppl):Abstract nr 1950.